Michael Aberman

Michael Aberman

Founder at Xenimmune Therapeutics, Inc.

53 year
Health Technology
Consumer Services
Finance

Profile

Dr. Michael S.
Aberman
is a General Partner at Regeneron Ventures and a Chief Executive Officer & Director at Xenimmune Therapeutics, Inc. He is on the Board of Directors at Halomine, Inc. and Xenimmune Therapeutics, Inc. Dr. Aberman was previously employed as a Senior VP-Strategy & Investor Relations by Regeneron Pharmaceuticals, Inc., a Research Analyst by Credit Suisse Securities (USA) LLC (Broker), a Research Associate by Morgan Stanley & Co., Inc., a Director-Business Development by Antigenics, Inc. (Delaware), and a President & Chief Executive Officer by Quentis Therapeutics, Inc. He received his undergraduate degree from Cornell University, an MBA from The Wharton School of the University of Pennsylvania and a doctorate degree from the University of Toronto.

Michael Aberman active positions

CompaniesPositionStart
Director/Board Member 02/11/2021
Founder -
All active positions of Michael Aberman

Former positions of Michael Aberman

CompaniesPositionEnd
Analyst-Equity 20/03/2010
Analyst-Equity 30/05/2006
AGENUS INC. Corporate Officer/Principal 29/02/2004
Chief Executive Officer -
REGENERON PHARMACEUTICALS, INC. Investor Relations Contact -
See the detail of Michael Aberman's experience

Training of Michael Aberman

University of Toronto Doctorate Degree
Cornell University Undergraduate Degree
The Wharton School of the University of Pennsylvania Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Michael Aberman's experience

Connections

100 +

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies2
REGENERON PHARMACEUTICALS, INC.

Health Technology

AGENUS INC.

Health Technology

Private companies5

Finance

Finance

Health Technology

Process Industries

Health Technology

See company connections
  1. Stock Market
  2. Insiders
  3. Michael Aberman